title: [Status and perspectives on chronic myeloproliferative neoplasm treatment].
abstract: Polycythaemia vera, essential thrombocytosis and primary myelofibrosis are closely related, clonal myeloproliferative neoplasms. Our knowledge of the underlying molecular mechanisms driving these diseases has increased dramatically during the latest ten years. Traditionally, treatment of these malignancies has focused on lowering their inherent thromboembolic risk but with the discovery of the JAK2-V617F mutation and most recently the calreticulin mutations new therapeutic options such as interferon-alpha, JAK2-inhibitors and statins are being contemplated. This article reviews these new treatment options.
authors.forename: Lukas Frans
authors.initials: LF
authors.lastname: Ocias
authors.forename: Morten Orebo
authors.initials: MO
authors.lastname: Holmström
authors.forename: Caroline Hasselbalch
authors.initials: CH
authors.lastname: Riley
authors.forename: Christen Lykkegaard
authors.initials: CL
authors.lastname: Andersen
authors.forename: Dorte
authors.initials: D
authors.lastname: Rønnov-Jessen
authors.forename: Jørn
authors.initials: J
authors.lastname: Starklint
authors.forename: Mikael
authors.initials: M
authors.lastname: Frederiksen
authors.forename: Morten Saabye
authors.initials: MS
authors.lastname: Steffensen
authors.forename: Ole Weis
authors.initials: OW
authors.lastname: Bjerrum
authors.forename: Sarah
authors.initials: S
authors.lastname: Farmer
authors.forename: Torben
authors.initials: T
authors.lastname: Mourits-Andersen
authors.affiliation: Hæmatologisk Afdeling, Roskilde -Sygehus, Køgevej 7-13, 4000 Roskilde. hans.hasselbalch@dadlnet.dk.
authors.forename: Hans Carl
authors.initials: HC
authors.lastname: Hasselbalch
authors.forename: Thomas Stauffer
authors.initials: TS
authors.lastname: Larsen
mesh_terms: D000465:Algorithms; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors; D009196:Myeloproliferative Disorders / Q000188:drug therapy*; D011087:Polycythemia Vera / Q000188:drug therapy; D055728:Primary Myelofibrosis / Q000188:drug therapy; D013922:Thrombocytosis / Q000188:drug therapy
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D016898:Interferon-alpha; D053614:Janus Kinase 2